Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease

Gastroenterology

Volumn 119, Issue 1, 2000, Pages 15-22

  Tibble, Jeremy A ^a,c   Sigthorsson, Gudmundur ^a   Bridger, Steven ^a   Fagerhol, Magne K ^b   Bjarnason, Ingvar ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^c ROYAL SUSSEX COUNTY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CALPROTECTIN; LACTULOSE; RHAMNOSE;

ACCURACY; ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CROHN DISEASE; DISEASE ACTIVITY; DISEASE MARKER; ENTERITIS; ERYTHROCYTE SEDIMENTATION RATE; FECES ANALYSIS; FEMALE; HUMAN; INTESTINE MUCOSA PERMEABILITY; MALE; PREDICTION; PRIORITY JOURNAL; RELAPSE; ULCERATIVE COLITIS;

EID: 0034234796     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/gast.2000.8523     Document Type: Article

References (41)

1. Saverymuttu SH. Clinical remission in Crohn's disease: Assessment using faecal Indium-111 granulocyte excretion. Digestion 1986;33:74-79.
2. Hodgson HJF. Prospects of new therapeutic approaches for Crohn's disease. Lancet 1999;353:425-426.
3. Lauritsen K, Laursen LS, Bukhave K, Rask Madsen J. Use of colonic eicosanoid concentrations as predictors of relapse in ulcerative colitis: Double blind placebo controlled study on sulphasalazine maintenance treatment. Gut 1988;29:1316-1321.
4. Louis E, Belaiche J, van Kemseke C, Franchimont D, de Groote D, Gueenen V, Mary JY. A high serum concentration of interleukin-6 is predictive of relapse in quiescent Crohn's disease. Eur J Gastroenterol Hepatol 1997;9:939-944.
5. Wright JP, Young GO, Tigler Wybrandi N. Predictors of acute relapse of Crohn's disease. A laboratory and clinical study. Dig Dis Sci 1987;32:164-170.
6. Kjeldsen J, Lauritsen K, De Muckadell OB. Serum concentrations of orosomucoid: Improved decision-making for tapering prednisolone therapy in patients with active inflammatory bowel disease? Scand J Gastroenterol 1997;32:933-941.
7. Schreiber S, Nikolaus S, Hampe J, Hamling J, Koop I, Groessner B, Lochs H, Raedler A. Tumour necrosis factor alpha and interleukin 1beta in relapse of Crohn's disease. Lancet 1999;353:459-461.
8. Brignola C, Iannone P, Belloli C, De Simone G, Bassein L, Gionchetti P, Belluzzi A, Campieri M, Barbara L. Prediction of relapse in patients with Crohn's disease in remission: A simplified index using laboratory tests, enhanced by clinical characteristics. Eur J Gastroenterol Hepatol 1994;6:955-961.
9. Cellier C, Sahmoud T, Froguel E, Adenis A, Belaiche J, Bretagne JF, Florent C, Bouvry M, Mary JY, Modigliani R. Correlations between clinical activity, endoscopic severity, and biological parameters in colonic or ileocolonic Crohn's disease. A prospective multicentre study of 121 cases. The Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives. Gut 1994;35:231-235.
10. Timmer A, Sutherland LR, Martin F. Oral contraceptive use and smoking are risk factors for relapse in Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study Group. Gastroenterology 1998;114:1143-1150.
11. Sahmoud T, Hoctin Boes G, Modigliani R, Bitoun A, Colombel JF, Soule JC, Florent C, Gendre JP, Lerebours E, Sylvester R. Identifying patients with a high risk of relapse in quiescent Crohn's disease. The GETAID Group. The Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives. Gut 1995;37:811-818.
12. Bjarnason I, MacPherson A, Hollander D. Intestinal permeability: An overview. Gastroenterology 1995;108:1566-1581.
13. Wyatt J, Vogelsang H, Hubl W, Waldhoer T, Lochs H. Intestinal permeability and the prediction of relapse in Crohn's disease. Lancet 1993;341:1437-1439.
14. Teahon K, Smethurst P, Macpherson AJ, Levi AJ, Menzies IS, Bjarnason I. Intestinal permeability in Crohn's disease and its relation to disease activity and relapse following treatment with elemental diet. Eur J Gastroenterol Hepatol 1993;5:79-84.
15. Dale IBP, Fagerhol MK, Scott H. Distribution of a new myelomonocytic antigen (L-1) in human peripheral blood leukocytes. Am J Clin Pathol 1985;84:24-34.
16. Fagerhol MK, Andersson KB, Naess-Andresen CF, Brandtzaeg P, Dale I. Calprotectin (the L1 leukocyte protein). In: Smith VL, Dedman JR, eds. Stimulus Response Coupling: The Role of Intracellular Calcium-binding Proteins. Boca Raton, FL: CRC Press, 1990:187-210.
17. Roseth AG, Fagerhol MK, Aadland E, Schjonsby H. Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study. Scand J Gastroenterol 1992;27:793-798.
18. Roseth AG, Aadland E, Jahnsen J, Raknerud N. Assessment of disease activity in ulcerative colitis by faecal calprotectin, a novel granulocyte marker protein. Digestion 1997;58:176-180.
19. Teahon K, Roseth A, Foster R, Bjarnason I. Faecal calprotectin: A simple sensitive quantitative measure of intestinal inflammation in man (abstr). Gastroenterology 1997;112(suppl):A1103.
20. Roseth AG, Schmidt PN, Fagerhol MK. Correlation between faecal excretion of indium-111-labelled granulocytes and calprotectin, a granulocyte marker protein, in patients with inflammatory bowel disease. Scand J Gastroenterol 1999;34:50-54.
21. Malchow H, Ewe K, Brandes JW, Goebell H, Ehms H, Sommer H. European cooperative Crohn's disease study (ECCDS): Results of drug reatment. Gastroenterology 1984;86:249-266.
22. Best WR, Becktel JM, Singleton JW. Rederived values of the eight coefficients of the Crohn's Disease Activity Index (CDAI). Gastroenterology 1979;77:843-846.
23. Harvey RF, Bradshaw JM. A simple index of Crohn's-disease activity. Lancet 1980;1:514.
24. Mahmud N, Stinson J, MA OC, Mantle TJ, Keeling PW, Feely J, Weir DG, Kelleher D. Microalbuminuria in inflammatory bowel disease. Gut 1994;35:1599-1604.
25. Mahmud N, McDonald GS, Kelleher D, Weir DG. Microalbuminuria correlates with intestinal histopathological grading in patients with inflammatory bowel disease. Gut 1996;38:99-103.
26. Powell-Tuck J, Day D, Bucknell N. Correlations between defined sigmoidoscopic appearance and other measures of disease activity in ulcerative colitis. Dig Dis Sci 1982;27:533-537.
27. Schroeder K, Tremaine W, Ilstrup D. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987;317:1625-1629.
28. Sigthorsson G, Tibble J, Hayllar J, Menzies I, Macpherson A, Moots R, Scott D, Gumpel MJ, Bjarnason I. Intestinal permeability and inflammation in patients on NSAIDs. Gut 1998;43:506-511.
29. Teahon K, Smethurst P, Levi AJ, Menzies IS, Bjarnason I. Intestinal permeability in patients with Crohn's disease and their first degree relatives. Gut 1992;33:320-323.
30. Tibble JA, Sigthorsson G, Foster R, Scott D, Fagerhol MK, Roseth A, Bjarnason I. High prevalence of NSAID enteropathy as demonstrated by a simple faecal test. Gut 1999;45:362-366.
31. Dale I, Brandtzaeg P, Fagerhol MK, Scott H. Distribution of a new myelomonocytic antigen (L1) in human peripheral blood leukocytes. Immunofluorescence and immunoperoxidase staining features in comparison with lysozyme and lactoferrin. Am J Clin Pathol 1985;84:24-34.
32. Cox D, Oakes D. Analysis of Survival Data. London: Chapman and Hall, 1984.
33. Kaplan E, Meier P. Nonparametric estimation for incomplete observations. J Am Statistical Assoc 1958;53:457-481.
34. Brignola C, Campieri M, Bazzocchi G, Farruggia P, Tragnone A, Lanfranchi GA. A laboratory index for predicting relapse in asymptomatic patients with Crohn's disease. Gastroenterology 1986;91:1490-1494.
35. Andre C, Descos L, Vignal J, Gillon J. C-reactive protein as a predictor of relapse in asymptomatic patients with Crohn's disease. Scott Med J 1983;28:26-29.
36. Hilsden RJ, Meddings JB, Hardin J, Gall DG, Sutherland LR. Intestinal permeability and post heparin plasma diamine oxidase activity in the prediction of Crohn's disease relapse. Inflamm Bowel Dis 1999;5:85-91.
37. Bjarnason I, Morain CO, Levi AJ, Peters TJ. Absorption of 51 chromium-labeled ethylenediaminetetraacetate in inflammatory bowel disease. Gastroenterology 1983;85:318-322.
38. Saverymuttu SH, Camilleri M, Rees H, Cavender TP, Hodgson HJF. Indium-111 granulocyte scanning comparison with colonoscopy, histology and faecal indium-111 excretion in assessing disease extent and activity in colitis. Gastroenterology 1986;90:1121-1128.
39. Saverymuttu SH, Peters AM, Lavender JP, Hodgson HJ, Chadwick VS. 111 Indium autologous leucocytes in inflammatory bowel disease. Gut 1983;24:293-299.
40. Teahon K, Bjarnason I. Comparison of leukocyte excretion and blood loss in inflammatory disease of the bowel. Gut 1993;34: 1535-1538.
41. Irvine EJ, Feagan B, Rochon J, Archambault A, Fedorak RN, Groll A, Kinnear D, Saibil F, McDonald JW. Quality of life: A valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group. Gastroenterology 1994;106: 287-296.